In a recent InvestorIntel interview, Chris Thompson spoke with Dr. Allen Davidoff, CEO of XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | FSE: ANU) about XORTX’s recent capital raise of over US$13.4 million as part of its uplisting to the NASDAQ and its deployment of funds as it plans several clinical trials for the next year.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Allen Davidoff explained that XORTX is a biotech pharma company focusing on developing therapies for kidney diseases including a treatment for kidney issues related to COVID-19. He went on to explain how XORTX has been focusing on progressive kidney diseases, an area where there are very few therapeutic options, and a “great opportunity” to develop drugs to satisfy this market. Dr. Davidoff mentioned that to reduce the business risk, XORTX focused on a drug that had already received a FDA “approvable letter” in the past, knowing that the safety and effectiveness of the drug is well defined, and then improved on the drug with “novel innovative formulations”. Finally, he said that as a biotech pharma company with two late-stage therapies entering into Phase 3 trials, there is a potential to sign co-development deals with a large pharma company that could benefit both parties.
To watch the full interview, click here.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225, a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
To learn more about XORTX Therapeutics Inc., click here
Leave a Reply